Fintel reports that on November 4, 2024, Craig-Hallum initiated coverage of PolyPid (NasdaqCM:PYPD) with a Buy recommendation.
Analyst Price Forecast Suggests 267.57% Upside
As of October 22, 2024, the average one-year price target for PolyPid is $12.24/share. The forecasts range from a low of $10.10 to a high of $14.70. The average price target represents an increase of 267.57% from its latest reported closing price of $3.33 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for PolyPid is 9MM. The projected annual non-GAAP EPS is -0.98.
What is the Fund Sentiment?
There are 14 funds or institutions reporting positions in PolyPid. This is an increase of 3 owner(s) or 27.27% in the last quarter. Average portfolio weight of all funds dedicated to PYPD is 0.20%, an increase of 20.05%. Total shares owned by institutions increased in the last three months by 33.52% to 1,470K shares.
What are Other Shareholders Doing?
Rosalind Advisors holds 679K shares representing 9.98% ownership of the company. In its prior filing, the firm reported owning 417K shares , representing an increase of 38.63%. The firm increased its portfolio allocation in PYPD by 8.45% over the last quarter.
AIGH Capital Management holds 479K shares representing 7.04% ownership of the company. No change in the last quarter.
DAFNA Capital Management holds 185K shares representing 2.72% ownership of the company. In its prior filing, the firm reported owning 185K shares , representing a decrease of 0.32%. The firm decreased its portfolio allocation in PYPD by 2.21% over the last quarter.
ADAR1 Capital Management holds 104K shares representing 1.53% ownership of the company.
Yelin Lapidot Holdings Management holds 11K shares representing 0.16% ownership of the company. No change in the last quarter.
Polypid Background Information
(This description is provided by the company.)
PolyPid Ltd. is a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
